![]() |
Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently… |
![]() |
FDA Defends Generic Drug Labeling Plan...
December 1, 2014 - Featured , In the News / Politics By: Nancy Simon, PharmD c/o 2016 – Last November, the Food and Drug Administration (FDA) submitted a proposal for a Generic Drug Labeling Plan. This new plan will allow generic drug companies to use the same process as the one used by brand drug companies to update their medication labels to reflect new safety information.1… |
![]() |
FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the… |
![]() |
Combating Counterfeit Drugs...
October 1, 2014 - Featured , In the News / Politics By: Azia Tariq, Staff Editor – With the sale of counterfeit drugs reaching an alarmingly higher rate than ever, The U.S Food and Drug Administration (FDA) in collaboration with the Skoll Global Threats Fund, the U.S. Pharmacopeia (USP), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the multi-agency… |
![]() |
An Interview with an FDA Preceptor: Pharmacist’s Role...
October 1, 2014 - Featured , Professional Advice / Opinions By: Melissa Roy Co-Copy Editor [Graphics focused] – Our dedicated preceptor Kimberly Defronzo, RPh, MS, MBA is currently a Consumer Safety Officer at the Food and Drug Administration (FDA). She attended the University of Connecticut School of Pharmacy for her Bachelors of Pharmacy. She then went to St. John’s University College of Pharmacy and Health… |
![]() |
Celiac Disease: Seeking Proper Treatment...
September 1, 2014 - Featured , In the News / Politics By: Sang Hyo Kim, Staff Editor – The Mayo Clinic reported in the American Journal of Gastroenterology that 1.8 million people in the United States suffer from celiac disease.1 More notably, of this population, over 75% of people are unaware that they even have this condition. While other studies have been conducted to determine the… |
![]() |
The Importance of the Measles Vaccine: Should We Be Vac...
July 1, 2014 - Featured , In the News / Politics By: Sherin Pathickal, PharmD Candidate c/o 2016 – The mandatory receipt of vaccinations as a preventive public health measure has long been a controversial issue in our society.1 Despite the popular use of immunizations, many reservations about vaccine constituents and their safety have prevailed, leading to increasing numbers of unvaccinated people.1 Opponents of vaccinations have… |
![]() |
Antipsychotic Use in the Elderly with Dementia...
July 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – The overuse of antipsychotics in the nursing home population for off-label indications continues to impact patient safety. In 2005, the FDA issued a black box warning that stated, “The treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality.” The evidence… |
![]() |
Evzio™ – New Naloxone Auto-Injector For Opioid Over...
June 1, 2014 - Featured , In the News / Politics By: Diana Gritsenko, PharmD Candidate c/o 2015 – Drug overdose is a serious problem in the United States. In 2010, drug overdose caused more deaths among adults within the ages of 25 and 64 years than motor vehicle accidents. The Center for Disease Control (CDC), ran an analysis that showed drug overdose death rates have… |
![]() |
FDA Approves Drug Elosulfase Alfa (Vimizim™) for Muco...
May 1, 2014 - Featured , In the News / Politics By: Erica Dimitropoulos Co-Copy Editor [Content- Focused] – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development… |
![]() |
Brown-Bag Event...
May 1, 2014 - Events , Featured By: Hayeon Na, Co-Copy Editor (Content Focused) – On February 26th, 2014, pharmacists, clinical faculty, and pharmacy students from St. John’s University College of Pharmacy and Health Sciences gathered at the Freeport Memorial Library for a “Brown Bag,” one of the yearly calendar events at the public library. This event was conducted through the joint… |
![]() |
New Strides in Lupus Treatment...
April 1, 2014 - Featured , In the News / Politics By: Daniel Mathan, PharmD Candidate c/o 2016, Anita Kachappilly, PharmD Candidate c/o 2016, & Amrita Singh, PharmD Candidate c/o 2015 – Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease that affects multiple organs in the body and can potentially become life threatening.1 The incidence of SLE is about 50 cases for every 100,000 people; it… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
Tasimelteon (Hetlioz®): First FDA Approved Pharmacolo...
April 1, 2014 - Featured , In the News / Politics By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and… |
![]() |
New Legislation Redefines Oversight for Compounding Pha...
April 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Senior Staff Editor – As the world of healthcare and its provision evolves, laws which organize and oversee the ways that patients receive health services must develop at the same pace. Last November, a new bill establishing clearer protocol for the compounding and tracking of medications became national law. The Drug Quality… |
![]() |
Prior Experience and the Growth of the Biosimilars Mark...
March 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Senior Staff Editor – In 21st century medicine, pharmaceuticals have come to include compounds derived through novel and complex methods. Some of the most recent innovations have been in the form of biologics, therapeutic compounds produced through biological processes.1 Biologics are derived from living cell lines which may be bacterial, yeast, animal,… |
![]() |
Methadone Associated Arrhythmias on the Rise...
March 1, 2014 - In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – Methadone maintenance therapy is prescribed for opioid dependency. Many HIV patients who were former injection drug abusers rely on methadone maintenance. Although there is limited data, research suggests lamivudine, ritonavir, and zidovudine to be the most common concomitant drugs in methadone associated torsades and prolonged QT interval.1… |
![]() |
Dietary Supplements and Their Potential Dangers...
March 1, 2014 - Professional Advice / Opinions By: Fatema Elias, Staff Writer – With the New Year and everyone committing to their New Year resolutions, more and more patients are coming into the pharmacy asking for recommendations, particularly for weight loss dietary supplements. I hesitate to recommend an over-the-counter dietary supplement for weight loss. However, we as pharmacists and pharmacy students have… |
![]() |
To Defend the People...
February 1, 2014 - Featured , Professional Advice / Opinions By: Davidta Brown, Senior Staff Editor – As the world’s largest market for pharmaceuticals, the United States receives many medications manufactured abroad.1 Patients, physicians, and pharmacists defer the responsibility of ensuring the quality of these imported drugs to the FDA, but it only takes one report of deceit in the pharmaceutical industry for this trust… |
![]() |
New Hepatitis C Drug Receives FDA Approval...
January 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – On November 22, 2013, simeprevir (Olysio®), a new agent to treat chronic hepatitis C, received approval under the FDA’s priority review program. Simeprevir is an NS3/4A protease inhibitor that blocks the replication of the hepatitis C virus. Two other drugs from the same class, boceprevir and telaprevir, which were… |
![]() |
Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase… |
![]() |
Possible Inhaled Option for Diabetics...
December 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Hospital Drug Shortages...
December 1, 2013 - Featured , In the News / Politics By: Hamid Razaki, PharmD – Drug shortages seen across pharmacies in the United States continue to be an issue in patient care. A drug product shortage is defined as a supply issue that affects how the pharmacy prepares or dispenses a drug product, or that influences patient care when prescribers must use an alternative agent.1… |
![]() |
Meet the President: An Interview with Father Levesque...
December 1, 2013 - Featured , Professional Advice / Opinions By: Beatrice Popovitz, Staff Editor and Ada Seldin, Staff Editor – In August 2013, St. John’s University welcomed Rev. Joseph L. Levesque, C.M., former president of Niagara University, into the community as interim president. Fr. Levesque has an elaborate background in Vincentian leadership and higher education, having taught in various religious institutions such… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
![]() |
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |
![]() |
Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms… |
![]() |
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
FDA’s New Warning: Acetaminophen Associated with Seri...
September 1, 2013 - Featured , In the News / Politics By: Andy Zhang, PharmD Candidate c/o 2015 – On August 1st, 2013, the U.S. Food and Drug Administration (FDA) released a new warning of serious acetaminophen associated skin reactions, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP).1 Acetaminophen is one of the most widely used over-the-counter (OTC) medication, and… |
![]() |
HIV Test: Making a Difference...
September 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – On June 27, 2013, the Centers for Disease Control and Prevention (CDC), AIDS.gov, and other national and local entities organized the 19th annual National HIV Testing Day. On this day, the theme of “Take the Test, Take Control” was employed to spread awareness of testing and prevention methods… |
![]() |
Children, Codeine, and Cytochrome P-450...
September 1, 2013 - Clinical , Featured By Davidta Brown, Staff Editor – For post-operative pain treatment, few drugs are as trustworthy, as tried-and-true, as codeine. Prescriptive confidence in the analgesic has promoted its use in children recovering from uncomplicated surgeries, but the spate of injuries and deaths of young children who had been given codeine after undergoing adenotonsillectomies has provoked a… |
![]() |
iPod, iPad, iPhone… iLimb...
August 1, 2013 - Featured , In the News / Politics By: Sang Hyo Kim, Staff Editor – There is a new invention called “i-limb ultra revolution,” which allows amputees to control their prosthetic hands with an Apple® app called “Bioism.” Designed by Touch Bionics in the United Kingdom, the new prosthetic hand has five individually powered fingers, including a powered rotating thumb and an auto-grasp… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Compounding at a Crossroads: New Boundaries in the Afte...
July 1, 2013 - Featured , In the News / Politics Davidta Brown, PharmD Candidate c/o 2017 – The debate on the nature of compounding practice and the extent to which it ought to be regulated has come to the forefront of public attention. Those who regularly follow American news and politics are familiar with the series of events that have led to the present… |
![]() |
The HIMSS Conference...
July 1, 2013 - Events By: Tina Chang & Helen Dong PharmD Candidates c/o 2014 Ever been to a conference where all you do is tweet all day? That’s exactly what we did at the New York State Healthcare Information and Management Systems Society (HIMSS) conference, where this year’s focus was on the role of health information technology in… |
![]() |
FDA Takes Major Strides Towards Opioid Abuse Prevention...
June 1, 2013 - Featured , In the News / Politics By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®… |
![]() |
Coffeehouse Chats...
June 1, 2013 - Events By: Ada Seldin and Moisey Rafailov, PharmD Candidates Class of 2015 – The “Coffeehouse Chats” is an annual Rho Chi Society Event that serves as a steppingstone to fostering professional relationships between students and faculty. The event provides a platform for students and professors to exchange experiences and ideas. This year, the event took place… |
![]() |
Helping Solve the Cruel Mystery...
June 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Senior Staff Editor – Lupus is highly unpredictable and occurs without warning; there is no known cause and no known cure. It affects over 1.5 million Americans, 90% of whom are women between the ages of 15 – 44.1 No two cases of lupus are alike, making it a very difficult disease… |
![]() |
FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen… |
![]() |
Regulation of Low to Moderate Risk Medical Devices by t...
May 1, 2013 - Featured , Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor [Content-Focused] – On March 22, 2013, Public Broadcasting Service (PBS) aired an episode of “Need to Know” on the safety of low to moderate risk medical devices. The episode closely followed the lawsuit of patient Linda Gross who has pelvic organ prolapse and was advised by her doctor to undergo… |
![]() |
College of Pharmacy and Health Sciences Hosts Year-End ...
May 1, 2013 - Events By: Tasnima Nabi, Senior Staff Editor – On May 2nd, St. John’s University College of Pharmacy and Health Sciences hosted the “Pre-Finals Relax, Refresh, Recharge Luncheon” on the Great Lawn. The event took place from 12:00 pm till 3:00 pm, with an array of activities. Students were able to picnic on the Great Lawn with… |
![]() |
AUVI-Q™: The Newest Epinephrine Device to Hit the Mar...
May 1, 2013 - In the News / Politics By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Most of us who work in a community pharmacy setting will usually get a few scripts a month for an Epi-pen™. An Epi-pen™ is a device that autoinjects epinephrine (also known as adrenaline) into a patient who is experiencing anaphylaxis. Anaphylaxis is a severe, whole-body allergic… |
![]() |
The Honors Program Spotlight...
April 1, 2013 - Events By: Steve Soman – The St. John’s University Honors Program features small classes, faculty mentoring, and an impressive number of academic and cultural opportunities for students to excel. These opportunities range from performances at the Metropolitan Opera, New York City Ballet, and the New York Philharmonic to museum visits and Manhattan walking tours. For students… |
![]() |
Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the… |
![]() |
U.S. v Caronia: Misdemeanor or Constitutional Right?...
March 1, 2013 - Featured , In the News / Politics By: Tamara Yunusova, Staff Editor – On December 3, 2012, the U.S. Second Circuit Court of Appeals became the first court in the nation to authorize off-label drug promotion under the First Amendment. The heavily-disputed ruling, which is headed for further appeal, will have far-reaching implications for pharmaceutical companies and drug regulation policy. In a… |